113 related articles for article (PubMed ID: 20220062)
1. Changes in magnetic resonance bone marrow angiogenesis on day 7 after induction chemotherapy can predict outcome of acute myeloid leukemia.
Hou HA; Shih TT; Liu CY; Chen BB; Tang JL; Yao M; Huang SY; Chou WC; Hsu CY; Tien HF
Haematologica; 2010 Aug; 95(8):1420-4. PubMed ID: 20220062
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival.
Shih TT; Hou HA; Liu CY; Chen BB; Tang JL; Chen HY; Wei SY; Yao M; Huang SY; Chou WC; Hsu SC; Tsay W; Yu CW; Hsu CY; Tien HF; Yang PC
Blood; 2009 Apr; 113(14):3161-7. PubMed ID: 18988863
[TBL] [Abstract][Full Text] [Related]
3. Dynamic contrast-enhanced MR imaging measurement of vertebral bone marrow perfusion may be indicator of outcome of acute myeloid leukemia patients in remission.
Chen BB; Hsu CY; Yu CW; Hou HA; Liu CY; Wei SY; Chou WC; Tien HF; Shih TT
Radiology; 2011 Mar; 258(3):821-31. PubMed ID: 21212370
[TBL] [Abstract][Full Text] [Related]
4. Study of prognostic significance of marrow angiogenesis assessment in patients with de novo acute leukemia.
AbdElAal Asmaa A; Afify RA; Zaher AE; ElGammal MM; Atef AM
Hematology; 2015 Oct; 20(9):504-10. PubMed ID: 25885121
[TBL] [Abstract][Full Text] [Related]
5. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia.
Chen X; Xie H; Wood BL; Walter RB; Pagel JM; Becker PS; Sandhu VK; Abkowitz JL; Appelbaum FR; Estey EH
J Clin Oncol; 2015 Apr; 33(11):1258-64. PubMed ID: 25732155
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment prognostic factors for overall survival in primary resistant acute myeloid leukemia.
Colovic N; Tomin D; Vidovic A; Suvajdzic N; Jankovic G; Palibrk V; Djunic I; Djurasinovic V; Virijevic M
Biomed Pharmacother; 2012 Dec; 66(8):578-82. PubMed ID: 23085253
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of rapid peripheral blood blast clearance during the initial course of induction chemotherapy in young patients with de novo acute myeloid leukemia.
Nakano H; Fujiwara SI; Ito S; Mashima K; Umino K; Minakata D; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
Hematol Oncol; 2017 Sep; 35(3):357-364. PubMed ID: 26639319
[TBL] [Abstract][Full Text] [Related]
8. Correlation of the proliferative index of residual leukemia with outcome in patients treated with sequential high dose ara-C and asparaginase.
Powell BL; Kute TE; Craig JB; Lyerly ES; Gregory BW; Do KA; Contento MM; Capizzi RL
Leukemia; 1990 May; 4(5):316-20. PubMed ID: 2388477
[TBL] [Abstract][Full Text] [Related]
9. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
10. Routine interim disease assessment in patients undergoing induction chemotherapy for acute myeloid leukemia: Can we do better?
Campuzano-Zuluaga G; Deutsch Y; Salzberg M; Gomez A; Vargas F; Elias R; Kwon D; Goodman M; Ikpatt OF; Chapman JR; Watts J; Vega F; Swords R
Am J Hematol; 2016 Mar; 91(3):277-82. PubMed ID: 26663264
[TBL] [Abstract][Full Text] [Related]
11. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
Krug U; Röllig C; Koschmieder A; Heinecke A; Sauerland MC; Schaich M; Thiede C; Kramer M; Braess J; Spiekermann K; Haferlach T; Haferlach C; Koschmieder S; Rohde C; Serve H; Wörmann B; Hiddemann W; Ehninger G; Berdel WE; Büchner T; Müller-Tidow C; ;
Lancet; 2010 Dec; 376(9757):2000-8. PubMed ID: 21131036
[TBL] [Abstract][Full Text] [Related]
12. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
[TBL] [Abstract][Full Text] [Related]
13. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
14. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup.
Büchner T; Schlenk RF; Schaich M; Döhner K; Krahl R; Krauter J; Heil G; Krug U; Sauerland MC; Heinecke A; Späth D; Kramer M; Scholl S; Berdel WE; Hiddemann W; Hoelzer D; Hehlmann R; Hasford J; Hoffmann VS; Döhner H; Ehninger G; Ganser A; Niederwieser DW; Pfirrmann M
J Clin Oncol; 2012 Oct; 30(29):3604-10. PubMed ID: 22965967
[TBL] [Abstract][Full Text] [Related]
15. Is the D14 bone marrow in acute myeloid leukemia still the gold standard?
Ofran Y
Curr Opin Hematol; 2016 Mar; 23(2):108-14. PubMed ID: 26717195
[TBL] [Abstract][Full Text] [Related]
16. [Modern strategies in therapy of acute myeloid leukemia (AML) in adulthood. I. Primary treatment of de novo AML].
Jehn U; Dengler R; Petrides PE
Internist (Berl); 1996 Jun; 37(6):661-8. PubMed ID: 8768003
[No Abstract] [Full Text] [Related]
17. All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of 'poor prognosis' acute myeloid leukemia.
Venditti A; Stasi R; Del Poeta G; Buccisano F; Aronica G; Bruno A; Pisani F; Caravita T; Masi M; Tribalto M
Leukemia; 1995 Jul; 9(7):1121-5. PubMed ID: 7630182
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging of the bone marrow in patients with acute leukemia during and after chemotherapy. Changes in T1 relaxation.
Jensen KE; Grundtvig Sørensen P; Thomsen C; Christoffersen P; Henriksen O; Karle H
Acta Radiol; 1990 Jul; 31(4):361-9. PubMed ID: 2206692
[TBL] [Abstract][Full Text] [Related]
19. Urinary excretion of proteolyzed alpha1-antitrypsin: specificity, quantitation, and relation to therapy response in patients with acute myeloid leukemia.
Dengler R; Plewan A; Münstermann U; Busch R; Eger G; Emmerich B
Clin Cancer Res; 1995 Feb; 1(2):199-205. PubMed ID: 9815974
[TBL] [Abstract][Full Text] [Related]
20. Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy.
Ling V; Burnett AK; Bradstock K; Seymour JF; Hills RK; Wei A
Br J Haematol; 2013 Mar; 160(6):861-3. PubMed ID: 23278846
[No Abstract] [Full Text] [Related]
[Next] [New Search]
